Hypoactive sexual desire disorder (HSDD)Female sexual dysfunctionErectile dysfunctionMale sexual arousal disordersMelanocortin system pharmacology
Typical dosing
1–12800 mcg · Variable — single bolus or pulsatile infusion depending on indication · Acute (single dose for IVF trigger) or short-term (days to weeks)
500–2000 mcg · As needed (45 min before activity, max 1 dose/24 hrs) · As needed, max 8 doses/month per FDA labeling
FDA status
Not FDA-approved. Investigational — multiple Phase 2 trials for IVF oocyte maturation and reproductive disorders. Kisspeptin-10 is on FDA's interim Category 2 list — substances FDA has identified as raising significant safety risks and intends to act against in compounding. No lawful compounding route.
FDA-approved as Vyleesi (bremelanotide, 2019) for premenopausal HSDD in women
